NCT05057013
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: HER3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 16 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic brain or leptomeningeal metastases – see trial for details
https://ClinicalTrials.gov/show/NCT05057013